Menu Back toSession 5: What Will the Generation and Application of RWE Look Like in 2030?

Real World Evidence Conference

This event is now offered in a new entirely virtual format.


Session 5: What Will the Generation and Application of RWE Look Like in 2030?

Session Chair(s)

Dorothee B. Bartels, PhD, MSc

Dorothee B. Bartels, PhD, MSc

  • Head of Global Real World Evidence and Digital Science
  • UCB Pharma, Belgium
Steven A. Anderson, PhD

Steven A. Anderson, PhD

  • Director, Office of Biostatistics and Epidemiology, CBER
  • FDA, United States
This session will explore what the successful generation and application of RWD and RWE might look like in 2030. It is expected that development of key elements such as robust data, validated methods and knowledge, as well as engagement of a broad range of interdisciplinary experts including data scientists, epidemiologists, statisticians, clinical scientists will be critical to acceptance of RWE in supporting claims of therapeutic effectiveness. Success may further include surmounting challenges such as integration of high-quality data from a variety of sources, development of new and innovative methods, bridging accross multiple disciplines and stakeholders and others. Panel members will discuss these and other critical elements necessary for the successful generation and application of real world evidence in 2030.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe two key elements necessary to the success of RWE application
  • Identify the experts needed to advance generation and use of RWE
  • Identify challenges to the potential successful application of RWE

Speaker(s)

Jon D. Duke, MD, MS

Speaker

Jon D. Duke, MD, MS

  • Director of Health Informatics
  • Georgia Tech Research Institute, United States
Richard  Forshee, PhD

Speaker

Richard Forshee, PhD

  • Associate Director for Analytics and Benefit-Risk Assessment, CBER
  • FDA, United States